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Background: Diabetes is fast gaining the status of a potential epi-
demic in India, with > 62 million individuals currently diagnosed 
with the disease.1 India currently faces an uncertain future in rela-
tion to the potential burden that diabetes may impose on the coun-
try. An estimated US$ 2.2 billion would be needed to sufficiently 
treat all cases of type 2 diabetes mellitus (T2DM) in India.2 Many 
interventions can reduce the burden of this disease. However, health 
care resources are limited; thus, interventions for diabetes treatment 
should be prioritized.
Objectives: The present study assesses the cost-effectiveness of anti-
diabetic drugs in patients with T2DM from Mumbai, India.
Methods: A prospective cross-sectional study was performed to 
assess the cost-effectiveness of antidiabetic drugs in patients with 
T2DM. Face-to-face interviews were conducted by using a validated 
questionnaire in a total of 152 (76 males, 76 females) patients with 
T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was 
determined on the basis of a drug’s cost, efficacy, adverse drug reac-
tions, safety of administration, frequency of administration, and 
bioavailability.
Results: The glimepiride plus pioglitazone combination was the 
most cost-effective (international normalized ratio [INR]: 3.7/unit 
of effectiveness), followed by glimepiride (INR: 6.6/unit of effective-
ness) prescribed in nonobese patients with T2DM. Glimepiride plus 
metformin was the most cost-effective (INR: 5.9/unit of effectiveness) 
followed by metformin (INR: 6.7/unit of effectiveness) prescribed in 
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obese patients with T2DM. Cost-effectiveness (INR/unit of effective-
ness) varied from 3.7 to 45.2. Seventeen percent of the patients with 
T2DM included in this study received less cost-effective antidiabetic 
drugs.
Conclusions: Prescriptions of cost-effective antidiabetic drugs (83%) 
were more common than less cost-effective antidiabetic drugs (17%) 
in patients with T2DM from Mumbai, India.
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